• The Scientist
    CELG Abraxane P3 panc ca studies likely to be a bust. Trial began 3/09; near end of trial 9/11, had to add 210 pts to the study
    Reply (2)
    • The Scientist: Only logical reason to add more pts was that OS data was weak; more pts were needed to raise OS data
    • The Scientist: SPARC recently shown to be beneficial in prostate CA pts.